Virtual Incision Corporation, a Lincoln, Neb. and Pleasanton, Calif.-based company developing advanced robotically assisted surgical devices, closed $11.2m equity financing.
The round was led by Bluestem Capital, with participation from existing investors PrairieGold Venture Partners.
The company intends to use the funds for a feasibility study on the use of miniaturized robotically assisted surgical technology for colon resection, a procedure performed to treat patients with lower gastrointestinal diseases such as diverticulitis, Crohn’s disease, inflammatory bowel disease and colon cancer.
Led by John Murphy, CEO, Virtual Incision developed a robot platform design that features a small, self-contained surgical device that is inserted in its entirety through a single incision in the patient’s abdomen. Designed to utilize existing tools and techniques familiar to surgeons, the company’s robot will not require a dedicated operating room or specialized infrastructure.
Virtual Incision’s robotically assisted surgical device is an investigational device and is not commercially available.